POLISCOPE
Back to feed

The civic record

Read. Follow. Verify.
High Impact

Congressional Hearing on Medicare Part B Drug Payment Experiment

Original title: THE OBAMA ADMINISTRATION'S MEDICARE DRUG EXPERIMENT: THE PATIENT AND DOCTOR PERSPECTIVE

Record date · January 1, 2017

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

What This Bill Does

This document is a transcript of a May 17, 2016, House Subcommittee on Health hearing regarding a proposed Obama Administration experiment to change how pays for prescription drugs. The hearing featured testimony from medical professionals, patient advocates, and policy experts regarding the potential impact of these changes on patient care and doctor practices.

Why it matters

The hearing focused on a that would alter drug reimbursement models, which directly affects how doctors are paid for administering drugs and how patients access specialized treatments.

Who It Affects

Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.

Directly affected

Medicare Part B beneficiaries

The proposed rule changes how drugs are reimbursed, which may impact access to or the cost of specialized treatments.

Directly affected

Physicians and medical practices

The rule alters the payment structure for administering prescription drugs under Medicare Part B.

Key Facts

  • The hearing was held on May 17, 2016, by the House Subcommittee on Health.
  • The subject was a proposed rule by the Centers for Medicare & Medicaid Services (CMS) regarding testing of Medicare Part B prescription drug models.
  • H.R. 5122 was introduced to prohibit further action on the proposed CMS rule.
  • Witnesses included representatives from the U.S. Oncology Network, the Coalition of State Rheumatology Organizations, the Immune Deficiency Foundation, and the Medicare Rights Center.
Show all 5 facts
  • The hearing included the submission of letters from various stakeholders, including AARP and members of Congress, addressed to the Department of Health and Human Services.

Frequently Asked Questions

What was the purpose of this hearing?
To examine a by the Obama Administration that would change how pays for prescription drugs and to hear perspectives from doctors and patients.
What is H.R. 5122?
It is a bill introduced by Representative Joseph R. Pitts that seeks to stop the implementation of the proposed drug payment experiment.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift100% confidence

Medicare Payment Reform

The document captures a specific moment of tension between the executive branch's attempt to reform drug payment models and congressional efforts to halt those changes.

Connected Entities

Joseph R Pitts, Debra Patt, Gene Green and 1 more
PersonJoseph R Pitts“Chairman of the Subcommittee on Health”Map →
PersonDebra Patt“Medical Director, U.S. Oncology Network”Map →
PersonGene Green“Ranking Member of the Subcommittee on Health”Map →
OrganizationCenters for Medicare & Medicaid Services“The federal agency proposing the drug payment experiment”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100
  • Significance80
    How much this matters to a regular citizen
  • Controversy75
    Intensity of disagreement among stakeholders
  • Entertainment20
    Compellingness for a non-policy-wonk reader
  • Buzz10
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record